Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) examined blood cell samples from 30 people who had contracted and recovered from Covid-19 prior to the emergence of virus variants.
The researchers found that one key player in the immune response to SARS-CoV-2 — the CD8+ T cell — remained active against the virus.
Also read: Covid-19: India vaccinated around 63 million people so far
The researchers intended to understand whether the T cells of the Covid-19 survivors could still recognise three SARS-CoV-2 variants found in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (B.1.1.248).
The researchers found that SARS-CoV-2-specific CD8+ T-cell responses remained largely intact and could recognise virtually all mutations in the variants studied.
Also read: Serum Institute gets DCGI approval to extend shelf-life of Covid vaccine
The researchers noted that their findings suggested that the T cell response in convalescent individuals, and most likely in vaccinees, are largely not affected by the mutations found in these three variants and should offer protection against emerging variants.
The findings were published in the journal Open Forum Infectious Diseases.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.